€903.60
Your prediction
Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.940% | 0.000% | 6.960% | 30.578% | 13.304% | 109.798% | 229.781% |
| Exact Sciences | -1.730% | -6.666% | -21.781% | -36.102% | -32.373% | -40.461% | -46.391% |
| Incyte Corp. | 0.570% | 6.599% | 6.275% | -11.824% | -7.473% | -22.406% | -24.720% |
| Amgen Inc. | -0.740% | -0.139% | 16.185% | 38.487% | 10.322% | 38.521% | 87.859% |
Comments
News
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.
Eli Lilly (NYSE: LLY) and Regeneron
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several